YahooOctober 15, 2026 at 10:30 AM NY12 Days Ago

Gilead and Vir forge $1.9bn pact to develop next-gen T-cell engagers

GILDGilead Sciences, Inc.

This deal sees Gilead double down on TCEs, following its first bet on the modality through its March buyout of autoimmune-focused Ouro Medicines.

What This Story Means

Read the Full Story at the Source

The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo